

Hansa Medical publishes prospectus regarding preferential rights issue at SEK 37 million

The Board of Directors of Hansa Medical AB (publ) have prepared a prospectus in Swedish only regarding the forthcoming issue of new shares. The issue of new shares will enable phase II-trials with the drug candidate IdeS in kidney transplantation. The Prospectus has today on the 19th of March 2014 been approved and registered with the Swedish Financial Supervisory Authority in accordance with the Financial Instruments Trading Act (1991:980).

The prospectus is available via the company's website, www.hansamedical.com, and via Remium Nordic AB's website, www.remium.com and will be available via the Swedish Financial Supervisory Authority website, www.fi.se/Register/Prospektregistret.

For further information, please contact:

Hansa Medical AB

Emanuel Björne, CEO

Mobile: 46 707 17 54 77

E-mail: emanuel.bjorne@hansamedical.com

www.hansamedical.com

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company's Certified Adviser. The information in this press release is such information that Hansa Medical AB (publ) is obliged to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. The information was made public on March 19, 2014 at 16:15 CET.